Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations
Public ClinicalTrials.gov record NCT03570619. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
IMPACT: Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations
Study identification
- NCT ID
- NCT03570619
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Enrollment
- 56 participants
Conditions and interventions
Interventions
- Ipilimumab Drug
- Nivolumab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 13, 2018
- Primary completion
- Dec 21, 2022
- Completion
- Mar 25, 2024
- Last update posted
- May 7, 2025
2018 – 2024
United States locations
- U.S. sites
- 8
- U.S. states
- 6
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California San Diego, Moores Cancer Center | San Diego | California | 92093 | — |
| University of California San Francisco/Helen Diller Family Comprehensive Cancer Center | San Francisco | California | 94158 | — |
| H. Lee. Moffitt Cancer Center & Research Institute, Inc. | Tampa | Florida | 33612 | — |
| Johns Hopkins University/Sidney Kimmel Cancer Center | Baltimore | Maryland | 21287 | — |
| University of Michigan Rogel Cancer Center | Ann Arbor | Michigan | 48109 | — |
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| Siteman Cancer Center at Washington University | St Louis | Missouri | 63110 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03570619, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 7, 2025 · Synced May 11, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03570619 live on ClinicalTrials.gov.